title: Farnesoid X receptor inhibits LNcaP cell proliferation via the upregulation of PTEN.
abstract: Prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. In the present study, the activation of the farnesoid X receptor (FXR), a member of the nuclear receptor superfamily, was demonstrated to inhibit cell proliferation in LNcaP cells. Using clinical samples, mRNA and protein levels of FXR were found to be significantly decreased by quantitative PCR and western blot analysis in prostate cancer tissues.In vitrostudies identified further that activation or overexpression of FXR suppressed prostate cancer cell proliferation as measured by BrdU incorporation assays. At the molecular level, the results further revealed that the expression of the tumor suppressor gene, PTEN, was upregulated by FXR activation. Therefore, the observations indicated that FXR functions as a tumor suppressor in prostate cancer, which may provide a novel method for molecular targeting cancer treatment.
authors.affiliation: Department of Urology Surgery, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China.
authors.forename: Jun
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Urology Surgery, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China.
authors.forename: Shi-Jun
authors.initials: SJ
authors.lastname: Tong
authors.affiliation: Department of Urology Surgery, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China.
authors.forename: Xiang
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Urology Surgery, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China.
authors.forename: Lian-Xi
authors.initials: LX
authors.lastname: Qu
keywords: GW4064; PTEN; farnesoid X receptor; prostate cancer